Kura Oncology (KURA) Given a $25.00 Price Target by Piper Jaffray Companies Analysts

Piper Jaffray Companies set a $25.00 target price on Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Monday morning. The firm currently has a buy rating on the stock.

KURA has been the topic of several other reports. BidaskClub downgraded shares of Kura Oncology from a hold rating to a sell rating in a report on Tuesday, October 9th. HC Wainwright set a $31.00 price target on shares of Kura Oncology and gave the company a buy rating in a report on Tuesday, August 7th. ValuEngine downgraded shares of Kura Oncology from a strong-buy rating to a buy rating in a report on Friday, October 19th. Cowen reiterated a buy rating on shares of Kura Oncology in a report on Monday, October 22nd. Finally, Zacks Investment Research downgraded shares of Kura Oncology from a buy rating to a hold rating in a report on Friday, November 9th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $26.86.

Shares of NASDAQ KURA opened at $14.05 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.76 and a current ratio of 14.76. The stock has a market cap of $483.07 million, a PE ratio of -9.24 and a beta of 4.41. Kura Oncology has a 12-month low of $10.20 and a 12-month high of $24.02.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.01. As a group, sell-side analysts expect that Kura Oncology will post -1.72 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. Millennium Management LLC grew its stake in Kura Oncology by 0.5% in the 2nd quarter. Millennium Management LLC now owns 524,872 shares of the company’s stock worth $9,553,000 after acquiring an additional 2,661 shares in the last quarter. Credit Suisse AG grew its stake in Kura Oncology by 36.7% in the 3rd quarter. Credit Suisse AG now owns 18,142 shares of the company’s stock worth $318,000 after acquiring an additional 4,869 shares in the last quarter. Rhumbline Advisers grew its stake in Kura Oncology by 30.7% in the 2nd quarter. Rhumbline Advisers now owns 23,647 shares of the company’s stock worth $430,000 after acquiring an additional 5,552 shares in the last quarter. Alliancebernstein L.P. grew its stake in Kura Oncology by 35.1% in the 3rd quarter. Alliancebernstein L.P. now owns 22,700 shares of the company’s stock worth $397,000 after acquiring an additional 5,900 shares in the last quarter. Finally, Alps Advisors Inc. grew its stake in Kura Oncology by 19.4% in the 2nd quarter. Alps Advisors Inc. now owns 48,400 shares of the company’s stock worth $881,000 after acquiring an additional 7,874 shares in the last quarter. Institutional investors own 79.28% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See Also: Earnings Per Share

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit